Early-stage development agreements for microRNA therapeutics show signs of interest from large pharma

June 29, 2010 | Analyst Insight

A biotech start-up jointly owned by Alnylam Pharmaceuticals and Isis Pharmaceuticals, Regulus Therapeutics has announced a drug development agreement with Sanofi-Aventis that will pay the early-stage company a $25 million...

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978